Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study. 

 -  2019 
<br/><br/><label>Index Terms--Occupation: </label><br/>MedStar Georgetown University Hospital Residents
<br/><br/><label>Index Terms--Curriculum Objective: </label><br/>Poster presented at